Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Banning, Antje ^a   Gülec, Christina ^a   Rouvinen, Juha ^b   Gray, Steven J ^c   Tikkanen, Ritva ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; MUTANT PROTEIN; N4 (BETA N ACETYLGLUCOSAMINYL)ASPARAGINASE;

AMINO ACID SEQUENCE; ANALYSIS; ASPARTYLGLYCOSAMINURIA; CHEMISTRY; DRUG EFFECT; ENDOPLASMIC RETICULUM; ENZYMOLOGY; FIBROBLAST; GENETICS; GOLGI COMPLEX; HEK293 CELL LINE; HELA CELL LINE; HUMAN; LYSOSOME; MALE; METABOLISM; MOLECULAR LIBRARY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHARMACOLOGY; THERAPEUTIC USE;

AMINO ACID SEQUENCE; ASPARTYLGLUCOSAMINURIA; ASPARTYLGLUCOSYLAMINASE; BASE SEQUENCE; ENDOPLASMIC RETICULUM; FIBROBLASTS; GOLGI APPARATUS; HEK293 CELLS; HELA CELLS; HUMANS; LYSOSOMES; MALE; MOLECULAR CHAPERONES; MUTANT PROTEINS; MUTATION; SMALL MOLECULE LIBRARIES;

EID: 84996548960     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep37583     Document Type: Article

References (41)

1. Opladen, T. et al. Aspartylglucosaminuria: unusual neonatal presentation in Qatari twins with a novel aspartylglucosaminidase gene mutation and 3 new cases in a Turkish family. J Child Neurol 29, 36-42 (2014).
2. Saarela, J. et al. Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations. Hum Mol Genet 10, 983-995 (2001).
3. Ikonen, E. et al. Spectrum of mutations in aspartylglucosaminuria. Proc Natl Acad Sci USA 88, 11222-11226 (1991).
4. Tikkanen, R., Enomaa, N., Riikonen, A., Ikonen, E. & Peltonen, L. Intracellular sorting of aspartylglucosaminidase: the role of N-linked oligosaccharides and evidence of Man-6-P-independent lysosomal targeting. DNA Cell Biol 14, 305-312 (1995).
5. Oinonen, C., Tikkanen, R., Rouvinen, J. & Peltonen, L. Three-dimensional structure of human lysosomal aspartylglucosaminidase. Nat Struct Biol 2, 1102-1108 (1995).
6. Tikkanen, R., Riikonen, A., Oinonen, C., Rouvinen, R. & Peltonen, L. Functional analyses of active site residues of human lysosomal aspartylglucosaminidase: implications for catalytic mechanism and autocatalytic activation. EMBO J 15, 2954-2960 (1996).
7. Saarela, J. et al. Activation and oligomerization of aspartylglucosaminidase. J Biol Chem 273, 25320-25328 (1998).
8. Ikonen, E. et al. Aspartylglucosaminuria: cDNA encoding human aspartylglucosaminidase and the missense mutation causing the disease. EMBO J 10, 51-58 (1991).
9. Mononen, I. et al. Aspartylglycosaminuria in the Finnish population: identification of two point mutations in the heavy chain of glycoasparaginase. Proc Natl Acad Sci USA 88, 2941-2945 (1991).
10. Dunder, U., Valtonen, P., Kelo, E. & Mononen, I. Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice. J Inherit Metab Dis 33, 611-617 (2010).
11. Kelo, E., Dunder, U. & Mononen, I. Massive accumulation of Man2GlcNAc2-Asn in nonneuronal tissues of glycosylasparaginase-deficient mice and its removal by enzyme replacement therapy. Glycobiology 15, 79-85 (2005).
12. Peltola, M. et al. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse. Gene Ther 5, 1314-1321 (1998).
13. Virta, S., Rapola, J., Jalanko, A. & Laine, M. Use of nonviral promoters in adenovirus-mediated gene therapy: reduction of lysosomal storage in the aspartylglucosaminuria mouse. J Gene Med 8, 699-706 (2006).
14. Boyd, R. E. et al. Pharmacological chaperones as therapeutics for lysosomal storage diseases. J Med Chem 56, 2705-2725 (2013).
15. Parenti, G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med 1, 268-279 (2009).
16. Parenti, G., Andria, G. & Ballabio, A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med 66, 471-486 (2015).
17. Arakawa, T., Ejima, D., Kita, Y. & Tsumoto, K. Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs. Biochim Biophys Acta 1764, 1677-1687 (2006).
18. Fan, J. Q. & Ishii, S. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. FEBS J 274, 4962-4971 (2007).
19. Ikonen, E., Enomaa, N., Ulmanen, I. & Peltonen, L. In vitro mutagenesis helps to unravel the biological consequences of aspartylglucosaminuria mutation. Genomics 11, 206-211 (1991).
20. Riikonen, A. et al. Primary folding of aspartylglucosaminidase. Significance of disulfide bridges and evidence of early multimerization. J Biol Chem 271, 21340-21344 (1996).
21. Tikkanen, R., Peltola, M., Oinonen, C., Rouvinen, J. & Peltonen, L. Several cooperating binding sites mediate the interaction of a lysosomal enzyme with phosphotransferase. EMBO J 16, 6684-6693 (1997).
22. Parenti, G., Moracci, M., Fecarotta, S. & Andria, G. Pharmacological chaperone therapy for lysosomal storage diseases. Future Med Chem 6, 1031-1045 (2014).
23. Autti, T. et al. Bone marrow transplantation in aspartylglucosaminuria-histopathological and MRI study. Neuropediatrics 30, 283-288 (1999).
24. Laitinen, A. et al. Two novel mutations in a Canadian family with aspartylglucosaminuria and early outcome post bone marrow transplantation. Clin Genet 51, 174-178 (1997).
25. Jalanko, A. et al. Mice with an aspartylglucosaminuria mutation similar to humans replicate the pathophysiology in patients. Hum Mol Genet 7, 265-272 (1998).
26. Kaartinen, V. et al. A mouse model for the human lysosomal disease aspartylglycosaminuria. Nat Med 2, 1375-1378 (1996).
27. Gray, S. J. Gene therapy and neurodevelopmental disorders. Neuropharmacology 68, 136-142 (2013).
28. Riikonen, A. et al. Dissection of the molecular consequences of a double mutation causing a human lysosomal disease. DNA Cell Biol 13, 257-264 (1994).
29. Sui, L., Lakshminarasimhan, D., Pande, S. & Guo, H. C. Structural basis of a point mutation that causes the genetic disease aspartylglucosaminuria. Structure 22, 1855-1861 (2014).
30. Wang, Y. & Guo, H. C. Two-step dimerization for autoproteolysis to activate glycosylasparaginase. J Biol Chem 278, 3210-3219 (2003).
31. Guan, C. et al. Activation of glycosylasparaginase. Formation of active N-terminal threonine by intramolecular autoproteolysis. J Biol Chem 271, 1732-1737 (1996).
32. Risley, J. M., Huang, D. H., Kaylor, J. J., Malik, J. J. & Xia, Y. Q. Glycosylasparaginase inhibition studies: competitive inhibitors, transition state mimics, noncompetitive inhibitors. J Enzyme Inhib 16, 269-274 (2001).
33. Xu, Q., Buckley, D., Guan, C. & Guo, H. C. Structural insights into the mechanism of intramolecular proteolysis. Cell 98, 651-661 (1999).
34. Su, Y. et al. Free glycine accelerates the autoproteolytic activation of human asparaginase. Chem Biol 20, 533-540 (2013).
35. Craig, S. A. Betaine in human nutrition. Am J Clin Nutr 80, 539-549 (2004).
36. Zhang, R. et al. Recovery of PEX1-Gly843Asp peroxisome dysfunction by small-molecule compounds. Proc Natl Acad Sci USA 107, 5569-5574 (2010).
37. Santana, A., Salido, E., Torres, A. & Shapiro, L. J. Primary hyperoxaluria type 1 in the Canary Islands: a conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. Proc Natl Acad Sci USA 100, 7277-7282 (2003).
38. Schueler, U. H. et al. Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J Inherit Metab Dis 27, 649-658 (2004).
39. Mussche, S. et al. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy. Hum Gene Ther 24, 209-219 (2013).
40. Tikkanen, R. et al. The dileucine motif within the tail of MPR46 is required for sorting of the receptor in endosomes. Traffic 1, 631-640 (2000).
41. Voznyi Ya, V. et al. Applications of a new fluorimetric enzyme assay for the diagnosis of aspartylglucosaminuria. J Inherit Metab Dis 16, 929-934 (1993).